Answers are grounded in this paper and cite their sources.
Psoriasis can occur on any body area, including the genitals. Genital involvement impacts quality of life, particularly intimacy/relationships. Topical treatment of genital psoriasis requires special considerations based on thinner skin and greater absorption. Roflumilast cream 0.3% and foam 0.3% are phosphodiesterase 4 inhibitor-based advanced targeted topical treatments that do not contain potentially irritating excipients; their efficacy and safety were demonstrated in patients with plaque psoriasis in the phase 3 DERMIS-1/2 and ARRECTOR trials, respectively. Efficacy and quality-of-life outcomes based on presence of genital involvement are reported here. Roflumilast cream 0.3% or foam 0.3%, or vehicle, were applied once daily for 8 weeks in eligible patients in the DERMIS-1/2 (aged ≥2 years with at least mild plaque psoriasis) and ARRECTOR (aged ≥12 years with psoriasis of the scalp [at least moderate] and body [at least mild]) studies, respectively. The primary endpoint of DERMIS-1/2 was Investigator Global Assessment (IGA) success at week 8 and the co-primary endpoints of ARRECTOR were IGA of the scalp (S-IGA) and body (B-IGA) success at week 8, each defined as clear (0) or almost clear (1) plus ≥2-point improvement from baseline. Additional assessments were Worst Itch-Numeric Rating Scale (WI-NRS), Dermatology Life Quality Index (DLQI), safety, and tolerability. At week 8, higher proportions of patients had improved psoriasis signs/symptoms with roflumilast versus vehicle for IGA/B-IGA success overall (DERMIS-1/2, 39.9% vs 6.5%; ARRECTOR, 45.5% vs 20.1%; both P<0.0001) and in those with baseline genital involvement (39.3% vs 5.4%; 45.1% vs 5.7%; both P<0.005), and for WI-NRS success overall (68.5% vs 31.3%; 63.1% vs 30.1%; both P<0.0001) and in those with baseline genital involvement (71.0% vs 16.7%, P<0.005; 63.6% vs 37.9%). At week 8, DLQI improved (minimally important difference, ≥4-point reduction from baseline in patients aged ≥17 years with baseline DLQI ≥4) with roflumilast versus vehicle overall (DERMIS-1/2, 73.3% vs 40.4%; ARRECTOR, 69.4% vs 36.2%; both P<0.0001) and in those with baseline genital involvement (64.4% vs 34.6%, P=0.0067; 81.8% vs 33.3%, P<0.001). Proportions of patients responding on the DLQI that their psoriasis caused no/no relevant ‘sexual difficulties’ increased more with roflumilast than with vehicle from baseline to week 8 in the overall population of DERMIS-1/2 (roflumilast, 79.7% to 92.1%; vehicle, 77.0% to 83.3%) and ARRECTOR (80.4% to 94.3%; 84.6% to 89.4%) and in those with baseline genital involvement in DERMIS-1/2 (61.1% to 84.2%; 81.6% to 80.0%) and ARRECTOR (52.2% to 90.2%; 75.0% to 78.3%). Similar trends were observed for improvements in ‘problems with partners or relatives. Application-site pain adverse events were reported for 6 (1.0%) and 1 (0.4%) patients in the roflumilast groups of DERMIS-1/2 and ARRECTOR, respectively. ≤2.1% of patients discontinued study medication because of an adverse event. ≥95.0% of patients reported no or mild irritation after the first roflumilast application. Roflumilast cream and foam were both well tolerated and improved signs/symptoms of plaque psoriasis and sexual function/relationships. Improvements in the overall population and in those with baseline genital involvement support both roflumilast cream and roflumilast foam for the treatment of psoriasis.
No takes yet. Share an insight, caveat, or question.
Payette et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: